Okumura et al. (34) reported that in early-stage MEC patients positive for CRTC1/3-MAML2 fusions, an excellent prognosis may be achieved without adjuvant radiotherapy when the tumors are completely resected without tumor spillage. This evidence concerns the gene MAML2 and neoplasm.